1. Home
  2. OR vs SYRE Comparison

OR vs SYRE Comparison

Compare OR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Osisko Gold Royalties Ltd

OR

Osisko Gold Royalties Ltd

HOLD

Current Price

$29.45

Market Cap

6.5B

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$97.27

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OR
SYRE
Founded
2014
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.5B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
OR
SYRE
Price
$29.45
$97.27
Analyst Decision
Hold
Strong Buy
Analyst Count
4
12
Target Price
$47.00
$85.08
AVG Volume (30 Days)
1.0M
1.7M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
0.60%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$105.04
N/A
Revenue Next Year
$20.68
N/A
P/E Ratio
$55.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.86
$14.51
52 Week High
$48.06
$102.06

Technical Indicators

Market Signals
Indicator
OR
SYRE
Relative Strength Index (RSI) 34.44 63.55
Support Level N/A $66.78
Resistance Level $37.82 $102.06
Average True Range (ATR) 1.10 5.24
MACD -0.20 0.38
Stochastic Oscillator 14.08 76.48

Price Performance

Historical Comparison
OR
SYRE

About OR Osisko Gold Royalties Ltd

OR Royalties Inc is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: